In the T2DM cohort, GSBR-1290 demonstrated a statistically significant reduction in HbA1c at week 12 (a decrease of -1.01% to -1.02%, placebo-adjusted)
Step 6: Visual Inspection Hold the vial up to a light source
Wash hands with soap and water, then allow them to air dry or use a clean paper towel
Results are viewable online
There are other forms of bias in these datasets including channeling (e.g., the prescribing pattern depends on a patient characteristic (particularly diabetes or obesity) that is a PDAC risk factor), detection (e.g., overreporting due to additional testing to rule out a suspected adverse event (e.g., imaging triggered by pancreas enzyme elevations)), and Weber effect (initial increase in event reporting shortly after drug launch) 49

GLP-1: New Metrics, New Molecules, New Prices Topics We Cover: 00:00 New data from Harvard/Mass General may classify nearly 70% of adults as having obesity 03:00 A new oral triple agonist shows record-setting absorption rates 07:00 Fractal Healths Revita procedure: weight maintenance after stopping GLP-1s 12:00 Zepbound vial prices drop (full breakdown by dose) 16:00 Daves personal experience switching off Mounjaro and intense hunger return 22:00 Novo Nordisks EVOKE/EVOKE+ Alzheimers trial: what the data really means 29:00 Why GLP-1 neurological research is just getting started 33:00 Updates on access, partners, and major news coming soon for Medicare patients If youre on Wegovy, Mounjaro, Zepbound, Saxenda, Trulicity, or compounded versions, this episode gives you the insight and context you need to have more competent and confident conversations with your doctor